Online citations, reference lists, and bibliographies.
← Back to Search

Biomarker Discovery And Clinical Proteomics.

J. Silberring, P. Ciborowski
Published 2010 · Computer Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis).Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity and specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue.Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.
This paper references
10.1002/PMIC.200600223
The pitfalls of proteomics experiments without the correct use of bioinformatics tools
D. Biron (2006)
Proteomic analysis of archival breast cancer serum.
B. Zeidan (2009)
10.1021/pr900443r
The proteomic analysis of primary cortical astrocyte cell culture after morphine administration.
P. Suder (2009)
10.1016/J.JCHROMB.2006.10.040
Methods for samples preparation in proteomic research.
A. Bodzoń-Kułakowska (2007)
10.1007/978-1-349-18559-7_6
Putting Things Together
A. Kleinknecht (1987)
10.1093/OXFORDJOURNALS.JHERED.A106073
Obese, a new mutation in the house mouse.
A. M. Ingalls (1996)
10.1002/pmic.200800686
Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin‐depleted samples
R. Gundry (2009)
10.1016/j.ab.2009.05.028
Protein-protein interaction studies on protein arrays: effect of detection strategies on signal-to-background ratios.
R. Hurst (2009)
10.1007/978-1-59745-117-8_14
Miniaturized parallelized sandwich immunoassays.
Hsin-Yun Hsu (2008)
10.1080/07357900802574660
Pharmacology and Pharmacogenetics of Chemotherapeutic Agents
S. Dawood (2009)
10.1126/SCIENCE.1696028
Searching for peptide ligands with an epitope library.
J. Scott (1990)
10.1021/ac900204f
Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry.
Eugene Ciccimaro (2009)
10.1074/mcp.R200007-MCP200
The Human Plasma Proteome
N. L. Anderson (2002)
10.1172/JCI26022
Differential exoprotease activities confer tumor-specific serum peptidome patterns.
J. Villanueva (2006)
10.1586/epr.09.67
Mass spectrometry-based clinical proteomics profiling: current status and future directions
P. Findeisen (2009)
10.1074/mcp.M500213-MCP200
Serum Microarrays for Large Scale Screening of Protein Levels *S
M. Janzi (2005)
10.1016/j.mad.2004.09.030
Protein microarrays: catching the proteome
O. Poetz (2005)
10.1002/RCM.384
Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry.
A. Pruvost (2001)
10.1002/prca.200780114
Sera proteomic biomarker profiling in HIV‐1 infected subjects with cognitive impairment
W. Rożek (2008)
10.1021/pr800451h
Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer.
L. Yan (2009)
10.1002/PMIC.200390057
Multi‐component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome
R. Pieper (2003)
10.1016/j.bbapap.2009.02.013
Identification of polyubiquitin binding proteins involved in NF-kappaB signaling using protein arrays.
Beau J. Fenner (2009)
10.1002/pmic.200800571
Plasma proteome analysis for anti‐obesity and anti‐diabetic potentials of chitosan oligosaccharides in ob/ob mice
S. G. Kumar (2009)
10.1002/PMIC.200300600
Protein microarrays: Promising tools for proteomic research
M. Templin (2003)
10.2741/3341
Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.
A. Westman-Brinkmalm (2009)
10.1016/0076-6879(93)17065-D
Libraries of peptides and proteins displayed on filamentous phage.
G. Smith (1993)
10.1039/B603004C
Chemogenomics: drug discovery's panacea?
E. Jacoby (2006)
10.1002/ELPS.200500167
Enrichment of low‐abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions
Hong-Lei Huang (2005)
10.1021/PR0600024
Different immunoaffinity fractionation strategies to characterize the human plasma proteome.
Yan Gong (2006)
10.1073/PNAS.89.21.10164
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.
C. Barbas (1992)
10.1097/PPO.0b013e3181bd0445
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
D. S. Tan (2009)
10.1074/mcp.M300026-MCP200
Efficient and Specific Removal of Albumin from Human Serum Samples*
L. Steel (2003)
10.1002/RCM.2783
Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry.
Eugene Ciccimaro (2006)
10.1002/RCM.3227
Targeted mass spectrometric strategy for global mapping of ubiquitination on proteins.
S. Mollah (2007)
10.1021/pr800904z
Stable Isotope Dilution Multidimensional Liquid Chromatography-Tandem Mass Spectrometry for Pancreatic Cancer Serum Biomarker Discovery
K. Yu (2009)
10.1002/pmic.200700733
Contact spotting of protein microarrays coupled with spike‐in of normalizer protein permits time‐resolved analysis of ERBB receptor signaling
C. Löbke (2008)
10.1038/nmeth.1260
Decision tree–driven tandem mass spectrometry for shotgun proteomics
D. Swaney (2008)
10.1016/j.copbio.2007.11.009
In situ synthesis of protein arrays.
Mingyue He (2008)
10.1038/nmeth.1333
A HUPO test sample study reveals common problems in mass spectrometry-based proteomics
A. Bell (2009)
10.1182/blood-2007-10-119438
Functional proteomic profiling of AML predicts response and survival.
S. Kornblau (2009)
10.1021/PR070220C
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment.
W. Rożek (2007)
10.1186/1477-5956-7-8
Biomarkers of HIV-1 associated dementia: proteomic investigation of sera
J. Wiederin (2008)
10.1158/0008-5472.CAN-04-3213
Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays.
J. Eckel-Passow (2005)
10.1385/1-59745-026-X:1
On-chip protein synthesis for making microarrays.
Niroshan Ramachandran (2006)
10.1021/PR050405O
Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF.
W. Wu (2006)
10.1038/372425A0
Positional cloning of the mouse obese gene and its human homologue
Y. Zhang (1994)
10.1038/354084A0
Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery
R. Houghten (1991)
10.1007/978-1-59745-545-9_11
Application of proteomics in cancer gene profiling: two-dimensional difference in gel electrophoresis (2D-DIGE).
D. Hariharan (2010)
10.1073/PNAS.73.6.2156
beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins.
L. H. Lazarus (1976)
10.1111/j.1749-6632.1988.tb26968.x
Vasoactive Intestinal Polypeptide and Related Peptides. Isolation and Chemistry a
V. Mutt (1988)
10.1021/PR049821J
Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry.
L. Desouza (2005)
10.1158/0008-5472.CAN-07-6854
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
K. Stemke-Hale (2008)
10.1016/J.CHROMA.2007.02.009
Start-to-end processing of two-dimensional gel electrophoretic images.
M. Daszykowski (2007)
10.3892/OR_00000426
Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.
M. W. Gast (2009)
10.1373/clinchem.2008.118505
SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.
M. Ueda (2009)
10.1073/PNAS.89.19.9339
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
C. Barbas (1992)
10.1074/mcp.M700354-MCP200
Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S
Hasmik Keshishian (2007)
10.1073/PNAS.89.8.3175
Human combinatorial antibody libraries to hepatitis B surface antigen.
S. Zebedee (1992)
10.1007/978-1-59745-117-8_6
Optimizing the difference gel electrophoresis (DIGE) technology.
D. Friedman (2008)
The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides.
R. Houghten (1992)
10.1073/PNAS.76.12.6666
Dynorphin-(1-13), an extraordinarily potent opioid peptide.
A. Goldstein (1979)
10.1371/journal.pone.0003740
Integrative MicroRNA and Proteomic Approaches Identify Novel Osteoarthritis Genes and Their Collaborative Metabolic and Inflammatory Networks
D. Iliopoulos (2008)
10.2174/157016206777709474
Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis.
P. Ciborowski (2006)
10.1074/mcp.T500003-MCP200
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma*
K. Sheehan (2005)
10.1186/1477-5956-6-26
Multidimensional protein fractionation using ProteomeLab PF 2D™ for profiling amyotrophic lateral sclerosis immunity: A preliminary report
Joshua D Schlautman (2008)
10.1021/PR0497632
Global proteome discovery using an online three-dimensional LC-MS/MS.
J. Wei (2005)
10.1016/j.jprot.2009.02.006
Protein arrays as tools for serum autoantibody marker discovery in cancer.
G. Kijanka (2009)
10.1038/sj.bjc.6604830
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
K. Metcalfe (2009)
10.1586/14789450.5.3.497
Identification of protein kinase substrates by proteomic approaches
S. Hattori (2008)
10.1093/CLINCHEM/47.8.1536
Overview of evidence-based medicine: challenges for evidence-based laboratory medicine.
M. McQueen (2001)
10.1002/jssc.200700271
A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity chromatography: Application to the analysis of obesity, diabetes, and hypertension diseases.
M. K. D. R. Dayarathna (2008)
10.1002/prca.200800043
Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease
W. Caudle (2008)
10.1002/prca.200800149
Protein microarrays as an application for disease biomarkers
Robert J. Caiazzo (2009)
10.1038/nmeth.f.255
A stress test for mass spectrometry–based proteomics
R. Aebersold (2009)
10.1038/nmeth.1210
Next generation high density self assembling functional protein arrays
Niroshan Ramachandran (2008)
10.1073/PNAS.88.22.10134
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
D. Burton (1991)



This paper is referenced by
10.1201/B15298-14
Identification of Biomarkers of Infectious Disease Using Surface-Enhanced Laser Desorption/Ionisation Mass Spectrometry
S. Hamilton (2013)
10.1371/journal.pone.0031031
Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers
G. Pottiez (2012)
Evaluation of the intra and interspecific variability in the genus Perkinsus. Proteomic analysis of the parasite and its interaction with the host
S. F. Boo (2015)
10.1016/j.oraloncology.2012.01.021
Saliva: a potential media for disease diagnostics and monitoring.
J. Liu (2012)
10.3892/OL.2015.3207
Screening and identification of apolipoprotein A-I as a potential hepatoblastoma biomarker in children, excluding inflammatory factors.
W. Zhao (2015)
10.4317/jced.55917
Salivary inflammatory proteins in patients with oral potentially malignant disorders
Valentina R. Dikova (2019)
10.1016/j.cca.2014.08.037
Emerging salivary biomarkers by mass spectrometry.
Q. Wang (2015)
10.1021/ac403233d
Efficient Separations of Intact Proteins Using Slip-Flow with Nano-Liquid Chromatography–Mass Spectrometry
Z. Wu (2014)
10.1016/j.jchromb.2012.12.005
Ultra high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: a review.
L. Denoroy (2013)
10.1007/978-3-642-28203-4
Microarrays in Diagnostics and Biomarker Development
B. Jordan (2012)
10.18875/2577-7890.3.103
Saliva as a Diagnostic Fluid for Neurological Disorder
Sanjita Kumari (2019)
10.1007/978-3-642-28203-4_8
Slow Off-Rate Modified Aptamer Arrays for Biomarker Discovery and Diagnostic Applications
J. Walker (2012)
10.1007/978-1-4614-8794-4_28
Protein Identification by Mass Spectrometry: Proteomics
Melinda S Wojtkiewicz (2014)
In search of the molecular profile characteristic of attention deficit hyperactivity disorder and of dyslexia
Jéssica Raquel Cortez Marques (2015)
10.1016/j.nbt.2011.11.016
Advances in human proteomics at high scale with the SOMAscan proteomics platform.
L. Gold (2012)
10.1159/000324310
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?
Anna Lucia Mastricci (2011)
10.1007/s00216-012-6420-x
Sulphur tracer experiments in laboratory animals using 34S-labelled yeast
J. G. Martínez-Sierra (2012)
10.5451/UNIBAS-005688706
Proteomic profiling of Duchenne muscular dystrophy : protein patterns and candidate markers of disease
Claudia Escher (2011)
10.1590/1414-462X201600020135
Towards a personalized risk assessment for exposure of humans to toxic substances
T. Pedrete (2016)
10.1021/pr3011809
Serum biomarkers reveal long-term cardiac injury in isoproterenol-treated African green monkeys.
Yashu Liu (2013)
10.1002/mas.21598
Proteome analysis of tissues by mass spectrometry.
Irena Dapic (2019)
10.1128/CMR.00021-13
Salivary Biomarkers: Toward Future Clinical and Diagnostic Utilities
Janice M. Yoshizawa (2013)
10.1016/j.ajpath.2011.10.024
Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array.
G. Baird (2012)
Electrochemical detection of biomolecules at liquid-liquid interfaces
S. O’Sullivan (2014)
10.1504/IJNT.2015.068877
Functionalised magnetic beads on gold surface for C-reactive protein detection
Hanen Chammem (2015)
10.1186/1479-5876-8-137
Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation
N. Haverland (2010)
10.1016/j.fertnstert.2014.07.1208
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research
N. Rahmioglu (2014)
10.1002/pmic.201300334
Antibody‐based proteomics and biomarker research—Current status and limitations
C. Solier (2014)
10.1007/978-1-61779-448-3_13
Proteomic Profiling of Cerebrospinal Fluid
G. Pottiez (2012)
10.15406/MOJCRR.2018.01.00005
Significance of salivary biomarkers as a drug monitoring aid
M. Mansoor (2018)
10.1038/NPRE.2010.4538.1
Aptamer-based multiplexed proteomic technology for biomarker discovery
L. Gold (2010)
10.1586/erm.10.110
Systematic antibody and antigen-based proteomic profiling with microarrays
B. Ayoglu (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar